BioHarvest Sciences (NASDAQ:BHST) announced a significant breakthrough, achieving large-scale production of plant-based exosomes using its proprietary bioreactors. This development leverages nano-sized vesicles to enhance the absorption and bioavailability of bioactive compounds, such as viniferin for skincare, and is expected to create substantial new revenue opportunities for BioHarvest through direct product development and as a contract manufacturing partner in the cosmetics, healthcare, and pharmaceutical industries. CEO Ilan Sobel highlighted this as an "exciting new monetization path," with a new skincare application anticipated within 18-24 months.
BioHarvest Sciences (NASDAQ:BHST) has announced a significant technological achievement by successfully producing plant-based exosomes at scale using its proprietary Botanical Synthesis platform. This development is notable as exosomes, which are nano-sized vesicles, offer a superior delivery mechanism for bioactive compounds due to enhanced absorption and bioavailability. The company has demonstrated this capability with viniferin, a polyphenol targeting the skincare market with known anti-aging and antioxidant properties. This breakthrough opens a dual-pathway commercialization strategy: direct product development, with management guiding for a new skincare application to be ready for market within 18-24 months, and a new potential revenue stream as a contract development and manufacturing organization (CDMO) for the cosmetic, healthcare, and pharmaceutical industries. CEO Ilan Sobel has framed this as a high-value monetization of the company's core technology, positioning BioHarvest to capitalize on growing industry interest in exosomes for therapeutic and cosmetic applications.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment